Drug Topics
AUGUST 26, 2022
Although further studies are needed to confirm the long-term effects, recent studies have shown the infliximab biosimilar to be a safe, effective, and cost reducing treatment for inflammatory bowel diseases.
Pharmacy Times
AUGUST 26, 2022
Additionally, approximately 70% who responded to the EnlivenHealth survey say that one-third or more of their revenue comes from individuals eligible for the government health insurance.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
AUGUST 26, 2022
Medicare users will see prescription drug pricing reform thanks to the Inflation Reduction Act.
Pharmacy Times
AUGUST 26, 2022
Pemigatinib is the first targeted therapy to gain FDA approval for the treatment of adult patients with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Board Vitals - Pharmacist
AUGUST 26, 2022
The American Board of Psychiatry and Neurology (ABPN) Certification Exam in Child Neurology is a board examination that tests a candidate’s knowledge of the fundamentals of child neurology. The exam is held once a year, and is required to become board certified in Child Neurology. We’ve compiled some of the most frequently asked questions about the test.
Pharmacy Times
AUGUST 26, 2022
Yoona Kim, PharmD, PhD, co-founder and CEO of Arine, discusses some of the key takeaways from the launch of Mark Cuban's pharmacy Mark Cuban Cost Plus Drug Co.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
AUGUST 26, 2022
The FDA has approved glycopyrrolate orally disintegrating tablets (Dartisla ODT; Edenbridge Pharmaceuticals) to reduce symptoms of peptic ulcer as an adjunct to peptic ulcer treatment in adults.
The Honest Apothecary
AUGUST 26, 2022
I am convinced that one of the reasons why so many healthcare professionals struggle when transitioning to management roles is the sheer messiness of it all. Medical folks are trained to insist upon good order, and rightly so. Chaos is the enemy of workplace safety and patient care. Doctors, nurses, and pharmacists generally prefer consistent and well-defined workflows and have a low tolerance for ambiguity.
Pharmacy Times
AUGUST 26, 2022
Routine depression screening in the primary care setting lowered screening disparities and increased recognition of symptoms for groups at risk of undertreatment, including racial and ethnic minority individuals and patients of older age.
European Pharmaceutical Review
AUGUST 26, 2022
Moderna has filed patent infringement lawsuits alleging that Pfizer and BioNTech’s COVID-19 vaccine Comirnaty ® infringes patents Moderna filed between 2010 and 2016 covering its foundational messenger RNA (mRNA) technology. The lawsuits were filed in the United States District Court for the District of Massachusetts and the Regional Court of Düsseldorf in Germany.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
AUGUST 26, 2022
Risk factors associated with declining health-related quality of life for adult survivors of childhood cancer, such as physical inactivity and chronic health conditions, should be targets of surveillance and intervention.
Drug Topics
AUGUST 26, 2022
More of these treatments have been approved, but supply chain issues and cost remain obstacles.
Pharmacy Times
AUGUST 26, 2022
Latanoprost (Xalatan) Sterile Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
European Pharmaceutical Review
AUGUST 26, 2022
Substandard and falsified medicines pose a significant threat to patients and health systems globally because they cause a range of problems from being ineffective to, in the worst case, causing severe adverse reactions and avoidable deaths. While the World Health Organization (WHO) reports that one in 10 essential medicines in low- and middle-income countries (LMICs) fail quality tests, because substandard and falsified medicines are often reported together – without distinguishing what pharmac
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
AUGUST 26, 2022
With the help of pharmacists and a team of health care providers, a better quality of life is possible for patients with Parkinson disease.
Pharmaceutical Technology
AUGUST 26, 2022
ElevateBio has signed a long-term strategic collaboration with the University of Pittsburgh, US, to establish a biomanufacturing centre for expediting cell and gene therapy development. Under the 30-year deal, ElevateBio will set up its next BaseCamp process development and Good Manufacturing Practice (GMP) manufacturing facility in Pittsburgh. This centre will be equipped with its supporting technologies, such as gene editing induced pluripotent stem cell (iPSC) and cell, vector and protein eng
Pharmacy Times
AUGUST 26, 2022
Training and knowledge about appropriate communication with individuals of diverse backgrounds improves adherence, outcomes.
pharmaphorum
AUGUST 26, 2022
The rivalry between Moderna and Pfizer/BioNTech in commercialising their COVID-19 vaccines has now spilled over into the courts, in the form of a patent infringement lawsuit. Moderna has filed complaints in the US and Germany claiming that the mRNA technology used to make Pfizer and BioNTech’s Comirnaty vaccine infringes multiple patents that cover its own Spikevax shot.
Pharmacy Times
AUGUST 26, 2022
As more biosimilars and specialty generics enter the market next year, this could result in a shift in drug spending.
Pharmaceutical Technology
AUGUST 26, 2022
Novartis has announced plans to completely spin off its generics and biosimilars division, Sandoz, to create a new publicly traded standalone firm. The latest development is intended to increase shareholder value by establishing a top European generics firm and a leader in biosimilars internationally. This will aid shareholders of Novartis to entirely take part in possible upside for Sandoz and Novartis Innovative Medicines businesses in the future.
Pharmacy Times
AUGUST 26, 2022
Industry partnerships will be essential to improving access to ketamine, according to expert Kevin Nicholson.
Pharmaceutical Technology
AUGUST 26, 2022
PathAI has expanded a multi-year partnership agreement with Bristol Myers Squibb (BMS) to leverage artificial intelligence (AI)-powered pathology in translational research and clinical trials. In the initial stage, the deal will focus on key translational research in oncology, fibrosis and immunology areas to advance the work into clinical development.
Pharmacy Times
AUGUST 26, 2022
A new study suggests that work and private life mental stressors are disrupting sleep in older employees, potentially wreaking havoc on health.
Fuld
AUGUST 26, 2022
Phronesis Partners and Fuld & Company today announced the appointment of Elaine Pratt to the role of Group Chief Marketing Officer. In this capacity, Elaine will lead the marketing strategy and activities for the two brands. By: Phronesis Partners and Fuld & Company. BOSTON – Aug 25, 2022 – Phronesis Partners and Fuld & Company, a fast-growing research, analytics, and advisory business, today announced the appointment of Elaine Pratt to the role of Group Chief Marketing Officer.
Pharmacy Times
AUGUST 26, 2022
Canakinumab did not meet the primary endpoint of disease-free survival in adult patients with stages II-IIIA and IIIB completely resected non-small cell lung cancer.
Pharmaceutical Technology
AUGUST 26, 2022
Amid a shortage of monkeypox vaccine doses, the WHO and FDA have declared public health emergencies, and the FDA has granted its first Emergency Use Authorization (EUA) to a monkeypox vaccine and opened the door for more. On August 4, the US Department of Health and Human Services (HHS) declared monkeypox a public health emergency, a move required to grant EUAs.
Pharmacy Times
AUGUST 26, 2022
Wellblends Immune & Respiratory is a 3-in-1 blend designed with ingredients to provide advanced immune support.
pharmaphorum
AUGUST 26, 2022
Aktis Oncology has gone back for another bite of the cherry in its Series A round, adding another $84 million to the $72 million raised last year to help bring its radiopharmaceuticals to market. The extension to the first round saw participation from the venture capital arm of Merck & Co plus other investors – Bristol-Myers Squibb and Novartis were already on board – and takes the total raised by the Massachusetts biotech to $161 million.
Pharmacy Times
AUGUST 26, 2022
Researchers find that the risk of developing dementia increased by 35% in patients with atrial cardiopathy.
pharmaphorum
AUGUST 26, 2022
Merck & Co’s negotiations with Seagen over a possible takeover have stalled because the two sides cannot agree on a price, according to Bloomberg, citing people familiar with the matter. The impasse is threatening the deal, says the report , although those involved said talks could still resume and lead to an agreement. Neither Merck nor Seagen have said they will comment.
Drug Topics
AUGUST 26, 2022
Your weekly roundup of the latest news from Drug Topics®.
PharmExec
AUGUST 26, 2022
Capsulomics announces leadership appointment of industry veterans Stacey Gilbert and Lisa Kann.
Pharma Times
AUGUST 26, 2022
The tool uses a series of connected algorithms that can assess if someone has PD from their nocturnal breathing
pharmaphorum
AUGUST 26, 2022
BioMarin Pharma has its landmark first approval for Roctavian – the first for a haemophilia gene therapy – and will now have to see if that can convert that into a viable business in Europe. The US biotech claimed conditional marketing approval from the European Commission for Roctavian (valoctocogene roxaparvovec) as a treatment for adults with severe haemophilia A, who don’t have a history of developing the antibodies that inhibit the activity of blood-clotting protein Factor VIII.
Expert insights. Personalized for you.
184 
Let's personalize your content